Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03, FiscalAI reports. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 31.45%. The business had revenue of $351.77 million during the quarter, compared to analyst estimates of $340.45 million.
Here are the key takeaways from Guardian Pharmacy Services’ conference call:
- Guardian raised its 2026 outlook, now expecting revenue of $1.43 billion–$1.45 billion and adjusted EBITDA of $129 million–$131 million, up from prior ranges of $1.40 billion–$1.42 billion and $123 million–$127 million, respectively.
- Second-quarter adjusted EBITDA increased 19% to $29.7 million, supported by an 18% increase in gross profit, favorable product and payer mix, purchasing leverage, labor productivity, and operating efficiencies.
- The company reported continued operating expansion, including high-single-digit growth in residents served and script volumes, the acquisition of Wellness Concepts in Virginia, and the launch of a greenfield pharmacy in Lexington, Kentucky.
- Guardian said IRA-related pricing reductions will continue to pressure reported revenue, with second-half revenue expected to decline year over year by a low-single-digit percentage; management expects underlying revenue growth to remain in the high-single digits and believes the margin impact has been mitigated.
- Approximately 13.5 million Class B shares are expected to convert into Class A shares in late September, and 35 million–37 million employee, management, and director-held Class A shares could become eligible for sale after the next trading window following the third-quarter results, creating a potential supply overhang.
Guardian Pharmacy Services Price Performance
NYSE:GRDN traded up $3.88 during trading hours on Friday, hitting $43.35. The stock had a trading volume of 1,045,061 shares, compared to its average volume of 277,924. The company has a 50 day simple moving average of $40.93 and a two-hundred day simple moving average of $37.09. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of 42.09, a P/E/G ratio of 2.59 and a beta of 0.10. Guardian Pharmacy Services has a one year low of $19.30 and a one year high of $47.02.
Institutional Investors Weigh In On Guardian Pharmacy Services
Analysts Set New Price Targets
A number of research firms have recently commented on GRDN. Bank of America raised their price target on Guardian Pharmacy Services from $42.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Oppenheimer boosted their price objective on Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a research note on Friday. Truist Financial increased their price objective on Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Wall Street Zen downgraded Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Zacks Research lowered Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Guardian Pharmacy Services has a consensus rating of “Moderate Buy” and an average target price of $43.83.
Read Our Latest Report on Guardian Pharmacy Services
Guardian Pharmacy Services Company Profile
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.
Read More
- Five stocks we like better than Guardian Pharmacy Services
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
